

# Olga Riabova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10192137/publications.pdf>

Version: 2024-02-01

28  
papers

775  
citations

567281

15  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

961  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. International Journal of Molecular Sciences, 2019, 20, 5868.	4.1	84
2	Quantitative Structure-Activity Relationship Studies of [(Biphenyloxy)propyl]isoxazole Derivatives. Inhibitors of Human Rhinovirus 2 Replication. Journal of Medicinal Chemistry, 2007, 50, 4205-4213.	6.4	73
3	<i>Per aspera ad astra</i>: application of Simplex QSAR approach in antiviral research. Future Medicinal Chemistry, 2010, 2, 1205-1226.	2.3	58
4	Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	49
5	Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. Journal of Antimicrobial Chemotherapy, 2005, 56, 648-656.	3.0	48
6	New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Research, 2009, 81, 56-63.	4.1	46
7	Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo. Scientific Reports, 2016, 6, 32487.	3.3	46
8	Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. Journal of Antimicrobial Chemotherapy, 2005, 55, 483-488.	3.0	45
9	Synthesis and antileprosy activity of some dialkyldithiocarbamates. Journal of Antimicrobial Chemotherapy, 2006, 57, 1134-1138.	3.0	41
10	Identification of individual structural fragments of N,N <sup>2</sup> -(bis-5-nitropyrimidyl)dispirotriperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. Journal of Antimicrobial Chemotherapy, 2007, 60, 68-77.	3.0	41
11	Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-a]pyrimidines and their analogs. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 37-39.	2.2	33
12	Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino <sup>2</sup> and Enteroviruses. ChemMedChem, 2015, 10, 1629-1634.	3.2	33
13	Competitive Fitness of Essential Gene Knockdowns Reveals a Broad-Spectrum Antibacterial Inhibitor of the Cell Division Protein FtsZ. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	28
14	Synthesis, cytotoxicity and antiviral activity of N,N <sup>2</sup> -bis-5-nitropyrimidyl derivatives of dispirotriperazine. Antiviral Research, 2002, 55, 117-127.	4.1	24
15	Copper-related toxicity in replicating and dormant<i>Mycobacterium tuberculosis</i> caused by 1-hydroxy-5- <i>R&lt;/i&gt;-pyridine-2(1-<i>H&lt;/i&gt;)-thiones. Metallomics, 2018, 10, 992-1002.</i></i>	2.4	22
16	QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3. Future Medicinal Chemistry, 2011, 3, 15-27.	2.3	17
17	Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. Antiviral Research, 2015, 123, 138-145.	4.1	14
18	New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. ACS Infectious Diseases, 2020, 6, 313-323.	3.8	11

#	ARTICLE	IF	CITATIONS
19	Transformations of 5- <i>n</i> -nitropyrimidines. <i>Journal of Heterocyclic Chemistry</i> , 2008, 45, 621-643.	2.6	9
20	6,11-Dioxobenzo[ <i>f</i> ]pyrido[1,2- <i>a</i> ]indoles Kill <i>Mycobacterium tuberculosis</i> by Targeting Iron-Sulfur Protein Rv0338c (IspQ), A Putative Redox Sensor. <i>ACS Infectious Diseases</i> , 2020, 6, 3015-3025.	3.8	9
21	Benzoylphenyl thiocyanates are new, effective inhibitors of the mycobacterial resuscitation promoting factor B protein. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017, 16, 69.	3.8	8
22	Machine Learning Models for <i>Mycobacterium tuberculosis</i> In Vitro Activity: Prediction and Target Visualization. <i>Molecular Pharmaceutics</i> , 2022, 19, 674-689.	4.6	8
23	The past, present and future of RNA respiratory viruses: influenza and coronaviruses. <i>Pathogens and Disease</i> , 2020, 78, .	2.0	7
24	Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. <i>Frontiers in Microbiology</i> , 2020, 11, 292.	3.5	5
25	Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against <i>Burkholderia cenocepacia</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 562.	3.5	5
26	Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 774-781.	2.8	5
27	A proof-of-concept study for the efficacy of dispirotripiperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis. <i>Antiviral Research</i> , 2022, 202, 105327.	4.1	4
28	Antiretroviral Activity Of a Novel Pyrimidyl-Di(Diazaspiroalkane) Derivative. <i>Acta Naturae</i> , 2017, 9, 105-107.	1.7	2